Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health Benefit Review Biomarkers topic
No spam. Unsubscribe anytime.
Committee advances health‑benefit review bill including biomarker mandate; advocates urge alignment with ACS recommendations
Summary
HB 6895, requiring health‑benefit reviews and collecting data on mandated benefits, was advanced to the floor. Members discussed including biomarker coverage and several asked for language changes to match advocacy guidance from the American Cancer Society.
The committee voted to send HB 6895 (LCO 5777) to the floor; the measure requires health‑benefit review processes, data collection on mandated benefits and includes language on biomarker coverage that originated in the Aging Committee.
Senator Lesser raised concerns that the biomarker language in the JFS draft differs materially from the American Cancer Society’s recommended language and asked leadership to work with advocates to tighten protections. Lesser said the current draft was “substantially different” and flagged that advocates seek robust protections for patients who need biomarker testing for diagnosis and treatment planning.
Senator Wong and other supporters described the health benefit review provisions as a transparency and accountability tool. Wong said the absence of full fiscal and coverage impact data makes it harder to weigh mandated benefits against affordability, and described the bill as an attempt to add clearer fiscal notes and periodic review.
Committee leadership said some provisions originally proposed for the bill (PKU language) were removed after staff determined they were already covered by state mandated benefits; the committee preserved a sunset for the review process and added exchange fiscal‑note requirements.
After discussion, the clerk called the roll and committee members approved forwarding the JFS language to the floor. Leadership committed to working with advocates on biomarker language as the bill moves forward.
